Who was studied?
Patients with advanced refractory solid tumors and malignant ascites.
What does the publication report?
A multicenter, single-arm study with dose finding followed by efficacy evaluation is proposed. It does not report completed trial results.
Safety findings
Dose-limiting toxicity evaluation is planned for phase I.
How should we interpret it?
This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study) · DOI: 10.1177/15330338241264169 · PMID: 39051686
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.